Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer
Condition: Early Gastric Cancer or Gastric Adenoma
MeSH terms: Stomach Neoplasms; Adenoma
Study type: Interventional

Summary: 
      Statins are commonly used as cholesterol-lowering medications and have shown effectiveness in
      the primary and secondary prevention of heart attack and stroke. In addition, several recent
      studies of human cancer cell lines and animal tumor models indicate that statins may have
      chemopreventive properties through the arresting of cell-cycle progression. The
      chemopreventive effect of statins was demonstrated in some kind of human tumors including
      colorectal cancer. In addition, recent one large epidemiologic study showed that statins
      decreased risk of gastric cancer. On the other hands, it has been well known that
      Helicobacter pylori infection induces gastric atrophy and intestinal metaplasia, which are
      premalignant lesions of gastric cancer. Progression of these premalignant lesions could be
      limited by H. pylori eradication. In addition, a recent double blind randomization study
      revealed that simvastatin as adjuvant to standard therapy improves significantly the H.
      pylori eradication rate. Therefore, investigators conjecture that statins may have an
      adjuvant role for inhibition of gastric carcinogenesis. investigators aim to evaluate the
      role of statins in gastric carcinogenesis by observing the changes of gastric inflammation
      under statins.
    


Intervention name(s): Arm1: Statin; Arm2: Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.
Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.; Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.
Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
Other intervention name(s): C10AA-Hmg coa reductase inhibitors
Intervention MeSH terms: Hydroxymethylglutaryl-CoA Reductase Inhibitors
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Statin; Gastric inflammation; Gastric cancer